NTLA at a glance
Intellia Therapeutics, Inc. (NTLA, SEC CIK 1652130) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Intellia Therapeutics, Inc. (NTLA) reported revenue of $67.7 million (up 16.9% from FY2024) and a net loss of $412.7 million. Diluted EPS was -$3.81.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Intellia Therapeutics, Inc. (NTLA) shares worth $1.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Dube Michael P on October 2, 2026 of 1,864 shares at $12.43 per share.
- In the last 90 days, NTLA insiders reported 0 open-market purchases ($0) and 4 open-market sales ($401K) on Form 4, a net sale of $401K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $67.7M
- +16.9% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$401K
- 13F holders
- 33 funds
- $1.5B · +2 vs prior quarter
- Latest 8-K
- Sep 8, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: biotechnology firm developing CRISPR-based in vivo genome editing therapies targeting severe diseases
- New emphasis on Phase 3 products lonvo-z and nex-z for hereditary angioedema and transthyretin amyloidosis, with commercial launch preparation for lonvo-z in H1 2027
- Strategic focus shifted towards advancing first-in-class systemic CRISPR therapies with single IV infusions in outpatient settings
- Employee count increased with shares issued to 116.3M from 102.0M year-over-year, net loss reduced to $412.7M from $519.0M in 2024
- Collaboration revenue grew to $67.7M from $57.9M, signaling stronger partner-based funding streams in 2025
Risk Factors
- Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
- Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility
- Operational risk: $195.1M committed lease payments starting mid-2026 for new Cambridge office/lab space could pressure cash flow
- Competitive risk: reliance on Regeneron collaboration contributing $23.7M in cost reimbursements subject to partnership risks
- Financial risk: $394.7M net cash used in operating activities in 2025, with runway into H2 2027 excluding milestones or new capital raises
Management Discussion & Analysis
- No capital allocation information such as buybacks, dividends, or capex mentioned
- Forward-looking statements referenced but no specific management outlook or guidance included
AI summary of the NTLA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $7.659M, down $6.586M YoY from $14.245M
- Operating loss $112.760M vs $109.996M; net loss $106.634M vs $101.255M
- Nex-z largest R&D program at $18.268M; lonvo-z $9.569M
- Lonvo-z HAELO attacks reduced 87% versus placebo; mean monthly rate 0.26 vs 2.10
- Lonvo-z BLA submission expected second half 2026; U.S. launch planned first half 2027 if approved
Risk Factors
- Newly added CRISPR validation risk: in-vivo genome-editing therapies remain largely unproven, with no such therapy approved in the U.S. or EU
- Most material update: FDA lifted MAGNITUDE and MAGNITUDE-2 clinical holds in Q1 2026 after Grade 4 liver injury and bilirubin elevations
- Regulatory risk: FDA may require additional toxicology, biodistribution, reproductive-health studies, or 15-year patient follow-up
- Near-term operational risk: MAGNITUDE and MAGNITUDE-2 resumption may face further regulatory or patient-safety delays
- Financial risk: continued net losses and no product-sales revenue create dependence on successful future commercialization
AI summary of the NTLA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- FDA accepted Intellia’s biologics license application for lonvoguran ziclumeran in hereditary angioedema
- Priority review accelerates FDA evaluation and potential U.S. approval timeline
Item EX-99.1: Item EX-99.1
- FDA accepted lonvo-z’s BLA with Priority Review, setting a March 10, 2027 PDUFA action date
- Potential first approved in vivo CRISPR therapy and only one-time HAE treatment, creating significant commercial differentiation if approved
Item 8.01: Other Events
- FDA accepted lonvo-z’s BLA for hereditary angioedema, advancing Intellia’s lead program into regulatory review
- Priority Review sets a March 10, 2027 PDUFA target action date, creating a defined approval catalyst
Item 2.03: Creation of a Direct Financial Obligation
- Intellia secured a non-dilutive debt facility with OrbiMed for up to $400 million
- Financing creates borrowing capacity without immediate equity dilution
Item 1.01: Entry into a Material Definitive Agreement
- $400M five-year senior secured facility, with $75M drawn at closing for working capital and general corporate purposes
- Additional borrowing tied to FDA BLA approval, lonvo-z revenue targets, and a $30M equity fundraising target
Item EX-99.1: Item EX-99.1
- $75 million funded upfront under a $400 million non-dilutive senior secured term loan
- Additional $225 million available through five milestone-based tranches, primarily tied to lonvo-z
Item 7.01: Regulation FD Disclosure
- Forward-looking disclosure centers on Credit Facility proceeds, milestone-based draws, and potential additional $100 million subject to lender agreement
- Additional borrowing depends on regulatory, revenue, and equity-financing milestones, creating execution and liquidity risk
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and business updates announced for quarter ended June 30, 2026
- Full financial and operating details contained in furnished Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Positive Phase 3 HAELO data: lonvo-z reduced attacks 87% versus placebo, with 62% attack-free and therapy-free versus 11%
- FDA BLA acceptance anticipated in second half of 2026, with potential U.S. launch in first half of 2027
AI summaries of NTLA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NTLA
Don't miss the next NTLA filing
- Alerts as it files. A push when NTLA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NTLA, by share count.
- Ask anything. An AI agent that reads every NTLA filing and answers with sources.
NTLA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Dube Michael P | Sell | Oct 2, 2026 | 1,864 | $12.43 |
| LEONARD JOHN M | Sell | Aug 21, 2026 | 2,785 | $13.00 |
| LEONARD JOHN M | Sell | Aug 20, 2026 | 19,890 | $12.60 |
| Dulac Edward J III | Sell | Jul 22, 2026 | 8,111 | $11.25 |
| Dulac Edward J III | Sell | Jul 2, 2026 | 4,677 | $18.00 |
| Dube Michael P | Sell | Jul 1, 2026 | 2,641 | $16.78 |
| Bhanji Muna | A | Jun 9, 2026 | 13,300 | - |
| Bhanji Muna | A | Jun 9, 2026 | 9,200 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $57.9M | $67.7M |
| Operating Income | - | -$534.3M | -$441.0M |
| Net Income | -$481.2M | -$519.0M | -$412.7M |
| Op. Margin | - | -923.1% | -651.7% |
| Net Margin | - | -896.8% | -609.9% |
| Balance Sheet | |||
| Total Assets | $1.3B | $1.2B | $842.1M |
| Equity | - | $872.0M | $671.4M |
| ROE | - | -59.5% | -61.5% |
| Per Share | |||
| EPS | $-5.42 | $-5.25 | $-3.81 |
| Cash Flow | |||
| Operating CF | - | -$348.9M | -$394.7M |
| CapEx | $14.0M | $5.8M | $1.1M |
Source: XBRL data in Intellia Therapeutics, Inc. (NTLA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NTLA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $1.53B |
| Q1 2026 | 31 | $945.6M |
| Q4 2025 | 30 | $657.8M |
| Q3 2025 | 31 | $1.15B |
| Q2 2025 | 30 | $575.4M |
| Q1 2025 | 24 | $363.4M |
| Q4 2024 | 21 | $497.0M |
| Q3 2024 | 15 | $468.5M |
- BlackRock+3.25M (+27%)
- FMR LLC (Fidelity)+2.71M (+131%)
- ARK Investment Management+2.37M (+16%)
- State Street Corp+2.31M (+33%)
- Vanguard Portfolio Management LLC+1.11M (+18%)
- Bank of America Corp−405.5K (-29%)
- Morgan Stanley−349.5K (-17%)
- Citadel Advisors LLC−293.5K (-64%)
- AQR Capital Management−137.6K (-22%)
- Invesco Ltd−22.7K (-5%)
- Renaissance Technologies LLC+1.40M
- Franklin Resources+10.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 215 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NTLA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 27, 2026 | - | Analysis | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- MYGN · MYRIAD GENETICS INCIn Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- QDEL · QuidelOrtho CorpIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
NTLA SEC filings: frequently asked questions
Are NTLA insiders buying or selling?
In the last 90 days, Intellia Therapeutics, Inc. (NTLA) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $401,237 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NTLA stock?
As of June 30, 2026, the largest Intellia Therapeutics, Inc. (NTLA) holders among the 13F filers tracked by SignalX were ARK Investment Management ($285.5 million), BlackRock ($260.7 million), State Street Corp ($156.3 million), Vanguard Portfolio Management LLC ($124.1 million), D.E. Shaw & Co ($109.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NTLA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Intellia Therapeutics, Inc. (NTLA) reported revenue of $67.7 million (up 16.9% from FY2024) and a net loss of $412.7 million. Diluted EPS was -$3.81. The figures come from the XBRL data in the 10-K.
What are the main risks in NTLA's latest 10-K?
In the 10-K filed February 26, 2026, Intellia Therapeutics, Inc. (NTLA) flagged: Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K. Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility. (AI summary of the Risk Factors section.)
What did NTLA report in its latest 8-K?
Intellia Therapeutics, Inc. (NTLA) filed an 8-K on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). FDA accepted Intellia’s biologics license application for lonvoguran ziclumeran in hereditary angioedema.
What are the latest NTLA SEC filings?
Intellia Therapeutics, Inc. (NTLA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on October 6, 2026.
What is NTLA's SEC CIK number?
Intellia Therapeutics, Inc. (NTLA)'s SEC Central Index Key (CIK) is 1652130. EDGAR lists every NTLA filing under that number.
Ask anything about NTLA
The research agent reads NTLA's filings, financials, insider trades and 13F holders, then answers with sources.